1131 related articles for article (PubMed ID: 28131992)
1. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
[TBL] [Abstract][Full Text] [Related]
2. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA Regulating ImMune Escape regulates mixed lineage leukaemia protein-1-H3K4me3-mediated immune escape in oesophageal squamous cell carcinoma.
Liu J; Zhou WY; Luo XJ; Chen YX; Wong CW; Liu ZX; Bo Zheng J; Yu Mo H; Chen JQ; Li JJ; Zhong M; Xu YH; Zhang QH; Pu HY; Wu QN; Jin Y; Wang ZX; Xu RH; Luo HY
Clin Transl Med; 2023 Sep; 13(9):e1410. PubMed ID: 37712124
[TBL] [Abstract][Full Text] [Related]
4. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
Zhang Y; Velez-Delgado A; Mathew E; Li D; Mendez FM; Flannagan K; Rhim AD; Simeone DM; Beatty GL; Pasca di Magliano M
Gut; 2017 Jan; 66(1):124-136. PubMed ID: 27402485
[TBL] [Abstract][Full Text] [Related]
5. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance.
Deng Y; Xia X; Zhao Y; Zhao Z; Martinez C; Yin W; Yao J; Hang Q; Wu W; Zhang J; Yu Y; Xia W; Yao F; Zhao D; Sun Y; Ying H; Hung MC; Ma L
Nat Commun; 2021 Dec; 12(1):7041. PubMed ID: 34873175
[TBL] [Abstract][Full Text] [Related]
8. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
[TBL] [Abstract][Full Text] [Related]
9. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
[TBL] [Abstract][Full Text] [Related]
10. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
[TBL] [Abstract][Full Text] [Related]
11. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
Wu Y; Sang M; Liu F; Zhang J; Li W; Li Z; Gu L; Zheng Y; Li J; Shan B
Carcinogenesis; 2020 Jul; 41(7):894-903. PubMed ID: 32529260
[TBL] [Abstract][Full Text] [Related]
14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
15. Regulation of cytokine and chemokine expression by histone lysine methyltransferase MLL1 in rheumatoid arthritis synovial fibroblasts.
Okamoto K; Araki Y; Aizaki Y; Tanaka S; Kadono Y; Mimura T
Sci Rep; 2024 May; 14(1):10610. PubMed ID: 38719857
[TBL] [Abstract][Full Text] [Related]
16. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.
Inoue S; Horiuchi Y; Setoyama Y; Takeuchi Y; Beck Y; Murakami T; Odaka A
J Surg Res; 2020 Sep; 253():201-213. PubMed ID: 32380346
[TBL] [Abstract][Full Text] [Related]
18. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
20. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
[No Abstract] [Full Text] [Related]
[Next] [New Search]